trending Market Intelligence /marketintelligence/en/news-insights/trending/3EwkfweWZof9vFd9-Y53jA2 content esgSubNav
In This List

FTC files complaint to block Illumina's acquisition of Pacific Biosciences

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


FTC files complaint to block Illumina's acquisition of Pacific Biosciences

The U.S. Federal Trade Commission filed a complaint to block Illumina Inc.'s planned $1.2 billion acquisition of Pacific Biosciences of California Inc.

The FTC expressed concerns that Illumina aims to "unlawfully maintain its monopoly" in the U.S. for DNA sequencing — used in genetic research and clinical testing — by buying Menlo Park, Calif.-based company Pacific Biosciences.

According to the complaint, PacBio in recent years has made advancements which make it a closer alternative to San Diego-based Illumina. Customers have switched some business to PacBio from Illumina, and the former is poised to take more business from the latter in the future, the FTC said.

Further, since the companies drive each other's innovation, the commission believes the deal will reduce efforts to innovate and develop new products.

The agency voted 5-0 to issue the administrative complaint and to authorize staff to seek a temporary restraining order and preliminary injunction, if needed, to prevent the transaction from moving forward. A trial is set to begin Aug. 18, 2020.

In September, Illumina extended the closing date of the acquisition to Dec. 31.

Illumina's stock dropped 1.31% to $323.45 at market close on Dec. 17, while Pacific Biosciences' stock fell 7.85% to $4.93 in the after-hours market.